Madrigal Pharmaceuticals signed a global licensing agreement with Ribo Life Science and Ribocure to acquire six preclinical siRNA programs targeting metabolic dysfunction‑associated steatohepatitis (MASH). The deal includes a $60 million upfront payment and up to $4.4 billion in development and commercial milestones, plus royalties. The collaboration gives Madrigal access to Ribo’s GalSTAR siRNA platform to pursue multi‑mechanistic RNAi approaches for MASH and opens possibilities for bi‑specific siRNAs. Madrigal framed the transaction as part of a broader push to build a comprehensive MASH pipeline following the commercial launch of Rezdiffra. Market observers note the deal furthers consolidation of MASH assets among established metabolic‑disease players and underscores continued appetite for RNAi modalities in liver disease; regulatory and competitive dynamics will determine the programs’ commercial value.